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Anapproachfor3Dbonetissuegenerationfromembryonicstem(ES)cellswasinvestigated.TheEScellswereinducedtodiﬀerentiate
into osteogenic precursors, capable of proliferating and subsequently diﬀerentiating into bone-forming cells. The diﬀerentiated cells
andtheseededscaﬀoldswerecharacterizedusingvonKossaandAlizarinRedstaining,electronmicroscopy,andRT-PCRanalysis.The
results demonstrated that ES-derived bone-forming cells attached to and colonized the biocompatible and biodegradable scaﬀolds.
Furthermore, these cells produced bone nodules when grown for 3–4 weeks in mineralization medium containing ascorbic acid and
beta-glycerophosphate both in tissue culture plates and in scaﬀolds. The diﬀerentiated cells also expressed osteospeciﬁc markers when
grown both in the culture plates and in 3D scaﬀolds. Osteogenic cells expressed alkaline phosphatase, osteocalcin, and osteopontin,
but not an ES cell-speciﬁc marker, oct-4. These ﬁndings suggest that ES cell can be used for in vitro tissue engineering and cultivation
of graftable skeletal structures.
INTRODUCTION
Although autogenous bone grafting remains the main
choice for treatment of bone fractures, bone defects, and
therapeutic arthrodesis, eﬃcacy is limited by donor mor-
bidity and the lack of tissue resource availability [1]. On
the other hand, alloplastic materials lack desired proper-
ties and consequently result in a high rate of failure [2].
Therefore, there is a great need for renewable sources of
materials based on the tissue engineering approach for
bone regeneration, repair, and replacement.
Embryonic stem (ES) cells are pluripotent cells de-
rived from the inner cell mass of preimplantation em-
bryos and represent embryonic precursor cells that give
rise to any cell type in the embryo [3]. When ES cells
are allowed to diﬀerentiate in a suspension culture, they
form spherical multicellular aggregates, called embryoid
bodies (EBs), which have been shown to contain a va-
riety of cell populations [4, 5]. Signiﬁcant progress has
been achieved in inducing murine ES (mES) cells to dif-
ferentiateintoparticulartypesofcells,suchashematopoi-
etic cells [6, 7], cardiomyocytes [8], smooth muscle cells
[9, 10], neurons [11, 12, 13, 14], and even organs such
as a functional gut-like unit [15] and pancreatic islet-like
organization [16]. Speciﬁcally, it has been shown that ES
cells can diﬀerentiate into osteogenic cells under selective
culture conditions [17, 18, 19, 20]. The osteogenic cells
arecapableofinvitroproducingextracellularorganicma-
trix of bone collagen 1 and osteocalcin (OC) [17]. The
ability of ES cells to in vitro diﬀerentiate into a variety
of cell types provides novel opportunities to use them
for new therapeutic strategies such as cell transplantation
and tissue and organ regeneration, replacement, and re-
pair.
The recent identiﬁcation of osteogenesis-related tran-
scription factors and osteoblast-speciﬁc markers has led
to a rapid advancement in understanding the process of
osteoblast diﬀerentiation [21]. Many growth factors and
cytokines have been shown to promote the diﬀerentia-
tion of osteoblasts, including insulin-like growth factor-
1[ 22], melatonin [23], and IL-6-related cytokines [24].
Bone morphogenic protein (BMP) family members have
been shown to exert particularly strong osteoinductive ef-
fects. It was recently found that compounds that are able
to upregulate the promoter of BMP 2 result in identiﬁ-
cation of statins, drugs of the HMG-CoA reductase in-
hibitor family [25, 26]. One of these drugs, compactin,
hasshownthepotentialofenhancingosteogenesisinmES
cells [26, 27].
It is believed that most organ cells, including os-
teoblast or osteoblast-like cells, are anchorage-dependent
and require speciﬁc environments for growth, which in-
clude the presence of a supporting scaﬀold [28]. This
3D scaﬀold will provide a supporting frame and act
as a template for osteogenesis. In order to permit the
ingress of bone cells and nutrients, a porous structure204 G. R. Chaudhry et al 2004:4 (2004)
with interconnected channels for 3D penetration is cru-
cial. The required characteristics of the material for the
scaﬀold include biocompatibility and biodegradability.
Various studies have been carried out to test the at-
tachment and spreading of osteoblast or osteoblast-like
cells on porous membranes or 3D scaﬀolds using col-
lagen, calcium phosphate, poly lactic acid (PLA), and
P L A ’ sc o p o l y m e r sw i t hg l y c o l i d e[ 29, 30, 31, 32, 33, 34,
35]. Particularly, recent work by Wiedmann-Al-Ahmad
et al [29] investigated the seeding and culture of human
osteoblast-like cells on several diﬀerent types of collagen.
These previous studies indicated that the seeding and cul-
ture of osteoblast-like cells strongly depend on various
factors of the scaﬀold material and its condition, such as
topography, chemistry, and surface energy [36, 37].
In the present study, we investigated a new approach
for3Dbonetissuegenerationfromstemcells.First,theES
cells were induced to diﬀerentiate into osteogenic precur-
sors, capable of proliferating and subsequently diﬀerenti-
ating into osteoblasts, bone forming cells. The osteogenic
cells were then seeded into a three dimensional scaﬀold
for in vitro bone tissue generation. The mES cells were
used to verify the feasibility of this approach. The ex-
perimental result showed that bone-forming cells derived
frommES cellscanbe seededinto aPLAscaﬀoldand sub-
sequently grow and form bone nodules under selective
cultivation conditions.
MATERIAL AND METHODS
Scaffold
OPLA scaﬀolds [38] from BD Biosciences, Billerica,
Mass, were used in the study. The BD OPLA scaﬀold
is a 3D synthetic polymer scaﬀold that is synthesized
from D,DL,L polylactic acid. This material has an open-
cell facetted architecture, which is eﬀective for cultur-
ing high density cell suspensions [38]. It is of cylindri-
cal shape, with a diameter of 4.2–5.2mm and a height
of 3.9–4.5mm. The ratio of dry weight to wet weight is
5.2mg/34mg. Average pore size ranges from 100–200µm.
The hydration capacity of the scaﬀold is 30µL. The mod-
ulus of elasticity at 25% strain is 0.92 ± 0.03 Mega Pascal.
During in vivo biodegradation, the scaﬀold is structurally
functional for 13 weeks and completely resorbed at the
end of 12 months.
Stemcellculture
ES cells (D3 [39], obtained from Dr K. Sue O’Shea,
University of Michigan, Mich) were maintained on
gelatin-coated dishes without feeder cells in Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10% fe-
tal bovine serum, 0.1mM 2-mercaptoethanol (Sigma, St
Lois, Mo), 0.1mM nonessential amino acids (Invitrogen,
Carisbad, Calif), 1mM sodium pyruvate (Sigma), and
1,000U/mL of leukemia inhibitory factor (LIF; Chemi-
con International Inc, Temecula, Calif).
DifferentiationofEScellstoembryoidbodies
E Sc e l l sw e r ec u l t u r e da sd e s c r i b e da b o v e .E B s
were prepared using the “hanging drop” method [17].
Approximately 1000 cells per 20µL were incubated on the
inverted lid of petri plates for three days. The resulting
EBs were then transferred to fresh petri plates and cul-
tured with 10−7 M cis-retinoic acid for three days with a
change of medium each day.
DifferentiationofEBstoosteogeniccells
To diﬀerentiate the EBs to osteogenic cells, the EBs
were transferred to gelatin-coated tissue culture plates in
ES medium supplemented with ascorbic acid phosphate
(50µg/mL) and β-glycerol phosphate (10mM) (mineral-
ization medium). The resulting cells were incubated un-
der the same condition for three weeks with a medium
change every 2 days.
Seedingofscaffold
The EBs were subjected to selective diﬀerentiation
of osteogenic cells in the mineralization medium as de-
scribed above and shown to produce bone nodules (see
Results). The diﬀerentiated cells were treated with trypsin
and the scaﬀolds were seeded as follows.
The scaﬀolds were placed in six-well tissue culture
plates (Fisher Scientiﬁc, Hanover, Ill) and seeded with
the osteogenic cells derived from EBs (a concentration of
200µLo f1 0 6 cells per mL). The cells were incubated for
0, 2, 4, and 8 hours at 37◦Ci n5 %C O 2 incubator be-
fore supplementing with 2.5mL of the culture medium,
and then incubated for 4 weeks with a medium change
every 2–3 days. Seeded and unseeded controls included
scaﬀolds seeded with and without ES cells, respectively,
and were incubated in the same way in the mineralization
medium. The scaﬀolds were periodically checked under
a light microscope and one set for each of the scaﬀolds
including controls (unseeded scaﬀolds) was sacriﬁced at
intervals of 0, 1, 2, 3, and 4 weeks, and analyzed by scan-
ning electron microscope for the purpose of monitoring
cell growth and production of bone nodules as well as ex-
pression of speciﬁc genetic markers. Simultaneously, six-
well culture plates with 100µLo f1 0 6 cells per mL were
incubated as above. One set of the wells was sacriﬁced at
intervals of 0, 1, 2, 3, and 4 weeks and analyzed as above.
All experiments were run in triplicates.
Histology
The osteogenic cells, after growing in the cell cul-
ture plates, were analyzed for bone mineral deposition
by the von Kossa staining method [40]. Brieﬂy, the cells
were rinsed twice with 10mM phosphate-buﬀered saline
(PBS), and then ﬁxed in 0.2% glutaraldehyde for 1 hour.
After rinsing in water, cells were dehydrated in ascending
ethanol series (70%, 90%, 100% ethanol) and then air
dried. The cells were rehydrated in a descending ethanol
series (100%, 90%, 70% ethanol) and water. The plates
were then stained with 2% silver nitrate for 1 hour,2004:4 (2004) Production of Bone Nodules by ESC-Derived Osteogenic Cells 205
Table 1. RT-PCR primers.
Gene Primer sequence Product size
oct-4
Sense GCAACTCAGAGGGAACCTCCT 62bp
Antisense TCTCCAACTTCACGGCATTG
Alkaline phosphate Sense AGGCAGGATTGACCACGG 138bp
Antisense TGTAGTTCTGCTCATGGA
Osteocalcin
Sense CTTGGGTTCTGACTGGGTGT 212bp
Antisense GCCCTCTGCAGGTCATAGAG
Osteopontin Sense TCACCATTCGGATGAGTCTG 436bp
Antisense ACTTGTGGCTCTGATGTTCC
exposed to a 70W lamp, rinsed in water, and counter-
stained in safranin for 2–3 minutes. Finally, the plates
were rinsed in 70% ethanol and observed. Alternatively,
cell culture was ﬁxed in 10% formalin-buﬀered saline for
20 minutes, washed with PBS, and stained for 10 minutes
with 1% Alizarin Red [41]. Plates were washed in running
tap water and then left to air dry. Bone mineral nodules
stained bright red.
Electronmicroscopicstudies
The cell colonization of the scaﬀold was analyzed by
scanning electron microscopy (SEM). The samples were
ﬁxed in 4% paraformaldehyde for 2 hours at room tem-
perature and incubated in 8% formaldehyde for 2 days at
4◦C. The samples were dehydrated in ascending ethanol
series (30%, 50%, 70%, 80%, 90%, one time each and
twice in 100%). After critical point drying, according to
standard procedure using liquid carbon dioxide, the sam-
ples were sputtered with gold-palladium and scanned us-
ing SEM (ISI model DS130).
For transmission electron microscopy (TEM), the
cells were ﬁxed in 3% glutaraldehyde in PBS for 3 hours at
room temperature. They were then washed with PBS for
30 minutes, post-ﬁxed with 1% osmium oxide in PBS for
45 minutes and washed overnight with PBS. The samples
were dehydrated in ascending ethanol series (50%, 60%,
70%, 80%, 90%, 100%), treated with Epon 812 at a ra-
tio of 1 : 3, 1 : 1, and 3 : 1 for 4 hours each and 100%
overnight. The samples were analyzed using TEM (Model
410, Philips FEI, Bruckmanrig, Germany).
ExtractionofRNAandRT-PCR
Cells were detached from the cell culture plates and
collected by centrifugation. The RNA from the cells was
extracted using Rneasy Kit (Qiagen Inc, Valencia, Calif)
following the manufacturer’s instructions. Analysis of the
RNA samples was performed using the one-step RT-PCR
kit(QiagenGmbH).PCRconditionsusedwereasfollows:
reverse transcription, 50◦C, 30 minutes; Taq polymerase
activation, 95◦C, 15 minutes; then thermal cycling, 94◦C,
30 seconds, 55◦C, 30 seconds, 72◦C, 30 seconds, for 35 cy-
cles; followed by a single elongation step at 72◦C, 10 min-
utes.Theprimersequencesandexpectedproductsizesare
100µ
Figure 1. Diﬀerentiation of mouse EBs in mineralization
medium.
listed in Table 1. RT-PCR products were analyzed by 1.5%
agarose gel electrophoresis.
RESULTS
DifferentiationofEScells
T h eE Sc e l l sf o r m e dE B sa f t e rap e r i o do f3d a y si n
suspension in the ES cell medium lacking Leukemia In-
hibitory Factor (LIF). The EBs were then plated in the
samemediumandtreatedwithretinoicacidfor3daysbe-
fore being transferred to the mineralization medium con-
taining beta-glycerophosphate and ascorbic acid. Retinoic
acid has been reported to be an important factor in osteo-
genesis of ES cells [17]. As shown in Figure 1, the EBs are
being diﬀerentiated into progenitor osteogenic cells (dif-
ferentiated cells are seen in the periphery of the EB). The
isolated cells displayed morphological features similar to
osteogenic cells (ie, osteoblasts and osteocytes) as shown
in Figure 2. Figure 2b shows the characteristic cytoplas-
mic extensions contacting the adjacent osteocytes when
grown for 4 weeks in the mineralization medium.
Electron micrographs of the ES and diﬀerentiated os-
teogenic cells are shown in Figure 3.T h ed i ﬀerentiated
cells exhibit characteristics of diﬀerentiated cells includ-
ing cellular organelles (Golgi apparatus and rough endo-
plasmic reticulum), which are not present in the ES cells.
Additional details of the diﬀerentiated cells are shown in
Figure 5.206 G. R. Chaudhry et al 2004:4 (2004)
100µ
(a)
400µ
(b)
Figure 2. Diﬀerentiation of ES cells to osteogenic cells.
(a) (b)
Figure 3. Electron micrographs of (a) ES cell and (b) osteogenic
cell.
Productionofbonenodules
The osteogenic cells grown for 3 to 4 weeks and sub-
jected to von Kossa staining showed spots of dark brown
coloration (Figure 4). Alizarin Red was also used to stain
the osteogenic cells (results not shown). ES cells, EBs, or
EBsdiﬀerentiatedintocellsotherthanosteogeniccellsdid
not stain under the same conditions. The results shown
in Figure 4 suggest that the diﬀerentiated osteogenic cells
produced bone nodules. Similarly, Phillips et al [27]h a v e
reported that osteogenic cells produced extracellular ma-
trix material that was stained by von Kossa staining.
Simultaneously, the diﬀerentiated cells derived from
EBs were analyzed by TEM. A comparison of ES cells
(Figure 3a) and the diﬀerentiated cells (Figure 5) shows
that the diﬀerentiated cell structure has an array of bone
nodules in the vicinity of well-developed and extensive
Figure 4. The von Kossa stain.
B
M
N
Figure 5. TEM micrograph of osteogenic cells producing bone
nodules. B: bone nodules; M: mitochondria; N: nucleus.
amount of mitochondria. Presence of a large number of
mitochondria supports the fact that the production of
bone nodules is an energy-demanding process.2004:4 (2004) Production of Bone Nodules by ESC-Derived Osteogenic Cells 207
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Figure 6. Scanning electron micrographs of scaﬀold seeded and unseeded with osteogenic cells and incubated in mineralization
medium. (a) Unseeded scaﬀold. (b) Seeded scaﬀold after 2 weeks of incubation. (c) Seeded scaﬀold after 4 weeks of incubation.
Growthofosteogeniccellsinscaffolds
Osteogenic cell growth, attachment, and invasion of
scaﬀold were investigated by the scanning electron micro-
scope. The results in Figure 6 show an extensive growth of
cellular biomass completely covering the scaﬀold as com-
pared to the control-unseeded scaﬀold. Growth and inva-
sion of the scaﬀolds by the osteogenic cells could be seen
after 1 week of incubation in mineralization medium.
No nodules were detected during the ﬁrst 2 and 3 weeks
in cell plates and scaﬀolds, respectively. After 4 weeks
of incubation of seeded scaﬀolds, small nodular patches
of excreted extracellular matrix (bone nodule structures)
could be seen. Production of bone nodules by the os-
teogenic cells seeded onto scaﬀolds and cultured on the
plate was judged by the von Kossa staining, as well as the
expression of osteospeciﬁc surface markers as determined
by the RT-PCR (see below). No nodular structures were
found in control scaﬀolds.
Molecularcharacterizationoftheosteoprogenitors
The ES cells exhibit expression of speciﬁc molecular
markers, such as oct-4 and several cell surface antigens.
The diﬀerentiated osteoprogenitors also express speciﬁc
markers, such as alkaline phosphatase (ALP), OC, and os-
teopontin(OP)[27].Weinvestigatedtheexpressionofse-
lected markers in both the ES cells and diﬀerentiated cells
producing bone nodules. The results of the experiments
are shown in Figure 7.T h eoct-4 was expressed only in
the ES cells but not in the EB cells. The expression of os-
teospeciﬁc markers, ALP, OP, and OC, was evident in the
diﬀerentiated cells that produced bone nodules. In some
cases, low levels of expression of OC was also detected
in messenger RNA that was derived from ES cell (results
not shown). The reason for this observation is an unusual
splicing event where one to several introns are retained
along with the exons. This result is the presence of higher
molecularweighttranscriptthatwillbeexpressedinmany
nonosseous tissues [42].
The ES-cell derived diﬀerentiated cells not only col-
onized the scaﬀolds but also produced bone nodules as
judged by the scanning electron micrography (Figure 6)
and von Kossa staining. The RT-PCR analysis of the tran-
scripts of the cells colonizing the scaﬀold showed expres-
sion of osteospeciﬁc markers. The mRNA from these cells
y i e l d e dR T - P C Ra m p l i ﬁ e dp r o d u c t so fA L P ,O C ,a n dO P .
DISCUSSION
Totipotent ES cells have been induced to diﬀerentiate
into a variety of cell types in vitro [6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16]. We present in this study that ES-cell-derived
osteoprogenitor cells attached to and colonized the scaf-
folds. These results show that ES cells can be used for tis-
sue engineering of bone structures/grafts. In vitro grown
bone grafts could facilitate skeletal reconstructions in
cases involving defects created by tumor resection, injury,
and skeletal abnormalities. The grafts developed from
the diﬀerentiated cells of well-characterized ES cells may
provide an alternative to allografts and nonbiodegrad-
able material such as bone cements and metals, espe-
cially titanium and ceramics. The use of allografts is dis-
advantageous due to donor morbidity [43, 44]. The non-
biodegradable materials do not promote bone ingrowth
[45].
Therefore, tissue engineering of bone structures and
their subsequent use as skeletal reconstruction bio-
materials, which are bioresorbable, biocompatible, not
toxic and which allow the bone ingrowth, are desirable.
Various studies have been carried out to test the attach-
ment and spreading of osteoblast or osteoblast-like cells
on porous membranes or 3D scaﬀolds using collagen,
calcium phosphate,PLA,andPLGA[29,30,31,32,33,34,
35]. Particularly, recent work by Wiedmann-Al-Ahmad
et al [29] investigated the seeding and culture of human
osteoblast-like cells on several diﬀerent types of collagen.
All previous studies indicated that the seeding and culture
of osteoblast-like cells strongly depend on various factors
ofthescaﬀoldmaterialanditscondition,suchastopogra-
phy,chemistry,andsurfaceenergy[36,37].Wefoundthat
the time interval between seeding of the osteogenic cells
into the scaﬀold and adding growth medium had little208 G. R. Chaudhry et al 2004:4 (2004)
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Figure 7. Agarose gel electrophoresis of RT-PCR products of mRNA isolated from ES cells, EBs, and osteogenic cells. In (a), lanes
1 and 2 show the RT-PCR product of oct4, and lane 3 shows molecular weight markers (1000, 700, 500, 400, 300, 200, 100, and
50bp). In (b), lanes 1 and 2 represent the RT-PCR product of OP from ES cells and EBs, respectively. Lanes 3 and 4 represent the
RT-PCR product of OP from osteogenic cells grown in the tissue culture plate and 3D scaﬀold, respectively. The arrow indicates the
molecular size of 400bp. In (c), lanes 1, 3, 4, and 5 represent the RT-PCR product of OC from the cells as described in (b) above. Lane
2 represents the molecular weight markers as described in (a).
or no eﬀect on colonization, production of bone nodules,
and expression of the osteospeciﬁc markers. These results
are contrary to the previous study [29] reporting that the
time interval between seeding osteoblasts and adding cul-
ture medium signiﬁcantly aﬀected the osteoblast prolif-
eration. However, osteoblasts used in this study were de-
rived from patients and were not derived from ES cells as
is the case in our study.
Theosteogeniccellsusedforthescaﬀoldseedingstudy
could be characterized as predominantly osteoblast-like
or osteoprogenitor since they produced bone nodules and
expressed osteospeciﬁc markers, ALP, OC, and OP [27].
ALP is an indicator for osteoblast-type cells and OC, an
extracellularnoncollagenousmatrixprotein,isexclusively
expressed by osteoblasts. However, in our study, no at-
tempt was made to isolate, grow, or determine types of
cells in the EB-derived cells. It is likely that the osteogenic
cells derived from EBs had multiple types of cell lineage.
Therefore, further investigation to enrich and prolong the
growth of osteoblast-type cells should be helpful for in
vitro tissue engineering and cultivation of graftable skele-
tal structures.
The use of ES cells as the source for generating
graftable skeletal tissues is advantageous compared with
existing sources (such as bone marrows) for bone tissue
engineering. The supply of autologous tissues and com-
patible bone-marrow-derived grafts is limited, while ES
cells can provide a renewable source for the production of
engineered grafts. ES cells can potentially yield compati-
ble grafts on sustained bases or they may be produced on
demand.
Inconclusion,ourstudydemonstratesthatosteogenic
cells can be derived from ES cells which can colonize and
grow when seeded into the biocompatible and biodegrad-
able scaﬀolds. Furthermore, these cells expressed os-
teospeciﬁc markers and produced bone nodules when
grown both in the culture plates and in 3D scaﬀolds.
Additional improvements in the protocol could allow cul-
tivation of graftable tissues. Further studies with other
biomaterials used as scaﬀolds should be helpful for iden-
tifying optimal conditions for in vitro cultivation of
graftable osseous structures.
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